{"id":10004,"date":"2018-02-23T13:02:33","date_gmt":"2018-02-23T05:02:33","guid":{"rendered":"https:\/\/id-ea.org\/tbe\/?p=10004"},"modified":"2022-10-26T11:20:35","modified_gmt":"2022-10-26T03:20:35","slug":"immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/","title":{"rendered":"Immune response to TBE infection or TBE vaccination? Differential serological analysis"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<div style=\"position: relative;\"><span style=\"position: absolute; right: -15px; top: 5px;\"><a href=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-News_Feb2018_final.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/02\/pdf_icon2.png\" width=\"45px\" height=\"45px\"><\/a><\/span><\/div>\n\n\n\n<div style=\"position: relative;\"><span style=\"position: absolute; right: -25px; top: 5px;\"><\/span><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Background<\/strong><br>The protection rate of TBE vaccination has been estimated at more than 95% according to field studies. <br>However, vaccine failures occur \u2013 often despite IgG antibodies being present in patients. Mostly, viral RNA cannot be detected at the onset of symptoms, and therefore, serological discrimination between vaccine-induced antibodies and those elicited by acute infection and measuring the immune response following vaccination is important. Non-structural protein 1 (NS1) is synthezised in TBE virus infected cells, but is not incorporated into TBE virus particles. Thus, NS1 is not present in (inactivated whole virus) TBE vaccines. Therefore, vaccinees should not develop NS1 antibodies and as a result serological response to NS1 should be a useful tool to distinguish between an immune response caused by an infection vs. antibodies induced from vaccination.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Results<\/strong><br>A suspension multiflex immunoassay (SMIA) has been developed by which an immune reponse can be analysed to TBE whole virus (WV) or NS1. Sera from 50 patients with high IgM and low IgG concentrations (according to commercial assays) were analysed by SMIA and for comparison, serum samples from 50 healthy individuals were analyzed \u2013 drawn i) on day 0 of vaccination, ii) 30 days after the second dose, and iii) 30 days after the third injection. All 50 acute-phase TBE samples showed WV-specific IgM measured by SMIA, and 46 patients also had NS1-specific IgM. In contrast, only seven of the serum samples from vaccinees had a (weak) IgM response to WV, and only one sample was slightly positive for NS1 IgM. All 50 samples from TBE patients had WV-specific IgG and 43 had developed NS1-IgG. In contrast, only three of the 150 samples (after one, two and three immunizations) had NS1-specific IgG.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The neutralisation IgG avidity index (AI) was low in acute phase patients and also in vaccinees after the first and second injection, while a pronounced increase of AI could be determined in vaccinees after three injections indicating that at least three doses of TBE vaccine are needed to achieve a high neutralising antibody avidity as measured by SMIA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Discussion<\/strong><br>The presence or absence of NS1-specific IgM\/IgG antibodies and the determination of IgG AI may help to discriminate between a serological response after an infection or vaccination and to analyse sera in detail (e.g. of immuno-compromized individuals and for seroprevalence studies). In addition, the use of SMIA may offer an alternative to neutralization tests for which a biosafety 3 level is required.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Literature<\/strong><br>Albinsson et al.<br>Distinction between serological responses following tick-borne encephalitis (TBEV) infection vs vaccination. Sweden 2017<br><em>Euro Surveill.<\/em> 2018; 23(3):pii=17-00838. <a href=\"https:\/\/doi.org\/10.2807\/1560-7917\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.2807\/1560-7917<\/a>.ES.2018. 23.3.17-00838<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Author: <strong>Dr. Michael Br\u00f6ker<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Compiled:<\/strong> February 2018<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>BackgroundThe protection rate of TBE vaccination has been estimated at more than 95% according to field studies. However, vaccine failures occur \u2013 often despite IgG antibodies being present in patients. Mostly, viral RNA cannot be detected at the onset of symptoms, and therefore, serological discrimination between vaccine-induced antibodies and those elicited by acute infection and measuring the immune response following vaccination is important. Non-structural protein 1 (NS1) is synthezised in TBE virus infected cells, but is not incorporated into TBE virus particles. Thus, NS1 is not present in (inactivated whole virus) TBE vaccines. Therefore, vaccinees should not develop NS1 antibodies and as a result serological response to NS1 should be a useful tool to distinguish between an immune response caused by an infection vs. antibodies induced from vaccination. ResultsA suspension multiflex immunoassay (SMIA) has been developed by which an immune reponse can be analysed to TBE whole virus (WV) or NS1. Sera from 50 patients with high IgM and low IgG concentrations (according to commercial assays) were analysed by SMIA and for comparison, serum samples from 50 healthy individuals were analyzed \u2013 drawn i) on day 0 of vaccination, ii) 30 days after the second dose, and iii) 30 days after the third injection. All 50 acute-phase TBE samples showed WV-specific IgM measured by SMIA, and 46 patients also had NS1-specific IgM. In contrast, only seven of the serum samples from vaccinees had a (weak) IgM response to WV, and only one sample was slightly positive for NS1 IgM. All 50 samples from TBE patients had WV-specific IgG and 43 had developed NS1-IgG. In contrast, only three of the 150 samples (after one, two and three immunizations) had NS1-specific IgG. The neutralisation IgG avidity index (AI) was low in acute phase patients and also in vaccinees after the first and second injection, while a pronounced increase of AI could be determined in vaccinees after three injections indicating that at least three doses of TBE vaccine are needed to achieve a high neutralising antibody avidity as measured by SMIA. DiscussionThe presence or absence of NS1-specific IgM\/IgG antibodies and the determination of IgG AI may help to discriminate between a serological response after an infection or vaccination and to analyse sera in detail (e.g. of immuno-compromized individuals and for seroprevalence studies). In addition, the use of SMIA may offer an alternative to neutralization tests for which a biosafety 3 level is required. LiteratureAlbinsson et al.Distinction between serological responses following tick-borne encephalitis (TBEV) infection vs vaccination. Sweden 2017Euro Surveill. 2018; 23(3):pii=17-00838. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018. 23.3.17-00838 Author: Dr. Michael Br\u00f6ker Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies. Compiled: February 2018<\/p>\n","protected":false},"author":241,"featured_media":13433,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[50],"tags":[],"coauthors":[172],"class_list":["post-10004","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immune response to TBE infection or TBE vaccination? Differential serological analysis - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immune response to TBE infection or TBE vaccination? Differential serological analysis - TBE Book\" \/>\n<meta property=\"og:description\" content=\"BackgroundThe protection rate of TBE vaccination has been estimated at more than 95% according to field studies. However, vaccine failures occur \u2013 often despite IgG antibodies being present in patients. Mostly, viral RNA cannot be detected at the onset of symptoms, and therefore, serological discrimination between vaccine-induced antibodies and those elicited by acute infection and measuring the immune response following vaccination is important. Non-structural protein 1 (NS1) is synthezised in TBE virus infected cells, but is not incorporated into TBE virus particles. Thus, NS1 is not present in (inactivated whole virus) TBE vaccines. Therefore, vaccinees should not develop NS1 antibodies and as a result serological response to NS1 should be a useful tool to distinguish between an immune response caused by an infection vs. antibodies induced from vaccination. ResultsA suspension multiflex immunoassay (SMIA) has been developed by which an immune reponse can be analysed to TBE whole virus (WV) or NS1. Sera from 50 patients with high IgM and low IgG concentrations (according to commercial assays) were analysed by SMIA and for comparison, serum samples from 50 healthy individuals were analyzed \u2013 drawn i) on day 0 of vaccination, ii) 30 days after the second dose, and iii) 30 days after the third injection. All 50 acute-phase TBE samples showed WV-specific IgM measured by SMIA, and 46 patients also had NS1-specific IgM. In contrast, only seven of the serum samples from vaccinees had a (weak) IgM response to WV, and only one sample was slightly positive for NS1 IgM. All 50 samples from TBE patients had WV-specific IgG and 43 had developed NS1-IgG. In contrast, only three of the 150 samples (after one, two and three immunizations) had NS1-specific IgG. The neutralisation IgG avidity index (AI) was low in acute phase patients and also in vaccinees after the first and second injection, while a pronounced increase of AI could be determined in vaccinees after three injections indicating that at least three doses of TBE vaccine are needed to achieve a high neutralising antibody avidity as measured by SMIA. DiscussionThe presence or absence of NS1-specific IgM\/IgG antibodies and the determination of IgG AI may help to discriminate between a serological response after an infection or vaccination and to analyse sera in detail (e.g. of immuno-compromized individuals and for seroprevalence studies). In addition, the use of SMIA may offer an alternative to neutralization tests for which a biosafety 3 level is required. LiteratureAlbinsson et al.Distinction between serological responses following tick-borne encephalitis (TBEV) infection vs vaccination. Sweden 2017Euro Surveill. 2018; 23(3):pii=17-00838. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018. 23.3.17-00838 Author: Dr. Michael Br\u00f6ker Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies. Compiled: February 2018\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-23T05:02:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-26T03:20:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Broeker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Broeker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/\"},\"author\":{\"name\":\"Michael Broeker\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/03f04d14182a6183d413e7ac1042c4bb\"},\"headline\":\"Immune response to TBE infection or TBE vaccination? Differential serological analysis\",\"datePublished\":\"2018-02-23T05:02:33+00:00\",\"dateModified\":\"2022-10-26T03:20:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/\",\"name\":\"Immune response to TBE infection or TBE vaccination? Differential serological analysis - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters.jpg\",\"datePublished\":\"2018-02-23T05:02:33+00:00\",\"dateModified\":\"2022-10-26T03:20:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immune response to TBE infection or TBE vaccination? Differential serological analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/03f04d14182a6183d413e7ac1042c4bb\",\"name\":\"Michael Broeker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g94a27e445c4371097d1dea87a2f962e9\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g\",\"caption\":\"Michael Broeker\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/michael-broeker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immune response to TBE infection or TBE vaccination? Differential serological analysis - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/","og_locale":"en_US","og_type":"article","og_title":"Immune response to TBE infection or TBE vaccination? Differential serological analysis - TBE Book","og_description":"BackgroundThe protection rate of TBE vaccination has been estimated at more than 95% according to field studies. However, vaccine failures occur \u2013 often despite IgG antibodies being present in patients. Mostly, viral RNA cannot be detected at the onset of symptoms, and therefore, serological discrimination between vaccine-induced antibodies and those elicited by acute infection and measuring the immune response following vaccination is important. Non-structural protein 1 (NS1) is synthezised in TBE virus infected cells, but is not incorporated into TBE virus particles. Thus, NS1 is not present in (inactivated whole virus) TBE vaccines. Therefore, vaccinees should not develop NS1 antibodies and as a result serological response to NS1 should be a useful tool to distinguish between an immune response caused by an infection vs. antibodies induced from vaccination. ResultsA suspension multiflex immunoassay (SMIA) has been developed by which an immune reponse can be analysed to TBE whole virus (WV) or NS1. Sera from 50 patients with high IgM and low IgG concentrations (according to commercial assays) were analysed by SMIA and for comparison, serum samples from 50 healthy individuals were analyzed \u2013 drawn i) on day 0 of vaccination, ii) 30 days after the second dose, and iii) 30 days after the third injection. All 50 acute-phase TBE samples showed WV-specific IgM measured by SMIA, and 46 patients also had NS1-specific IgM. In contrast, only seven of the serum samples from vaccinees had a (weak) IgM response to WV, and only one sample was slightly positive for NS1 IgM. All 50 samples from TBE patients had WV-specific IgG and 43 had developed NS1-IgG. In contrast, only three of the 150 samples (after one, two and three immunizations) had NS1-specific IgG. The neutralisation IgG avidity index (AI) was low in acute phase patients and also in vaccinees after the first and second injection, while a pronounced increase of AI could be determined in vaccinees after three injections indicating that at least three doses of TBE vaccine are needed to achieve a high neutralising antibody avidity as measured by SMIA. DiscussionThe presence or absence of NS1-specific IgM\/IgG antibodies and the determination of IgG AI may help to discriminate between a serological response after an infection or vaccination and to analyse sera in detail (e.g. of immuno-compromized individuals and for seroprevalence studies). In addition, the use of SMIA may offer an alternative to neutralization tests for which a biosafety 3 level is required. LiteratureAlbinsson et al.Distinction between serological responses following tick-borne encephalitis (TBEV) infection vs vaccination. Sweden 2017Euro Surveill. 2018; 23(3):pii=17-00838. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018. 23.3.17-00838 Author: Dr. Michael Br\u00f6ker Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies. Compiled: February 2018","og_url":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/","og_site_name":"TBE Book","article_published_time":"2018-02-23T05:02:33+00:00","article_modified_time":"2022-10-26T03:20:35+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters.jpg","type":"image\/jpeg"}],"author":"Michael Broeker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael Broeker","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/"},"author":{"name":"Michael Broeker","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/03f04d14182a6183d413e7ac1042c4bb"},"headline":"Immune response to TBE infection or TBE vaccination? Differential serological analysis","datePublished":"2018-02-23T05:02:33+00:00","dateModified":"2022-10-26T03:20:35+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters.jpg","articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/","url":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/","name":"Immune response to TBE infection or TBE vaccination? Differential serological analysis - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters.jpg","datePublished":"2018-02-23T05:02:33+00:00","dateModified":"2022-10-26T03:20:35+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/immune-response-to-tbe-infection-or-tbe-vaccination-differential-serological-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Immune response to TBE infection or TBE vaccination? Differential serological analysis"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/03f04d14182a6183d413e7ac1042c4bb","name":"Michael Broeker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g94a27e445c4371097d1dea87a2f962e9","url":"https:\/\/secure.gravatar.com\/avatar\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g","caption":"Michael Broeker"},"url":"https:\/\/tbenews.com\/tbe\/author\/michael-broeker\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/10004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/241"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=10004"}],"version-history":[{"count":8,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/10004\/revisions"}],"predecessor-version":[{"id":20011,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/10004\/revisions\/20011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/13433"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=10004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=10004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=10004"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=10004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}